Literature DB >> 8934584

Multiple test procedures for dose finding.

A C Tamhane1, Y Hochberg, C W Dunnett.   

Abstract

The problem of identifying the lowest dose level for which the mean response differs from that at the zero dose level is considered. A general framework for stepwise testing procedures that use contrasts among the dose level means is proposed. Using this framework, several new procedures are derived. These and some existing procedures, including that of Williams (1971, Biometrics 27, 103-117; 1972, Biometrics 28, 519-531), are compared analytically and by an extensive simulation study for the normal theory balanced one-way layout case. It is pointed out that the procedures based on the so-called step and basin contrasts proposed by Ruberg (1989, Journal of American Statistical Association 84, 816-822) have excessively high type I familywise error rates (FWEs) and, hence, they should not be used. Some findings of the simulation study are as follows: For monotone dose mean configurations, Williams' procedure and two step-down test procedures based on Helmert and linear contrasts offer the best performance. For nonmonotone dose mean configurations, the performance of Williams' procedure does degrade somewhat, but the other two procedures are still the best. For more complex designs, a simple step-down test procedure that uses any alpha-level tests (not necessarily t-tests) to compare each dose level with the zero dose level controls the FWE and is the only alternative available, but its power is rather low, especially under nonmonotone configurations. Step-up procedures are generally dominated by step-down procedures when the same contrasts are used although the differences are not great.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934584

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic.

Authors:  Maiying Kong; Shesh N Rai; Roberto Bolli
Journal:  Stat Biopharm Res       Date:  2014-01-02       Impact factor: 1.452

2.  Simultaneous confidence bands for comparisons to placebo, with application to detecting the minimum effective dose.

Authors:  Julia N Soulakova; Allan R Sampson; Gang Jia; Leon J Gleser
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Practical considerations for optimal designs in clinical dose finding studies.

Authors:  Frank Bretz; Holger Dette; Jose C Pinheiro
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

4.  Expected loss functions as additional measures to assess performance of multiple testing procedures for combination drug dose finding.

Authors:  Julia N Soulakova; Allan R Sampson
Journal:  Pharm Stat       Date:  2012-03-06       Impact factor: 1.894

5.  Defining physiologically "normal" vitamin D in African Americans.

Authors:  N C Wright; L Chen; J Niu; T Neogi; K Javiad; M A Nevitt; C E Lewis; J R Curtis
Journal:  Osteoporos Int       Date:  2011-12-22       Impact factor: 4.507

6.  The timing of administration of a clinically relevant dose of losartan influences the healing process after contusion induced muscle injury.

Authors:  Tetsuo Kobayashi; Kenji Uehara; Shusuke Ota; Kimimasa Tobita; Fabrisia Ambrosio; James H Cummins; Satoshi Terada; Freddie H Fu; Johnny Huard
Journal:  J Appl Physiol (1985)       Date:  2012-11-15

7.  A note on confidence bounds after fixed-sequence multiple tests.

Authors:  Yi-Hsuan Tu; Bin Cheng; Ying Kuen Cheung
Journal:  J Stat Plan Inference       Date:  2012-11-01       Impact factor: 1.111

8.  On Identifying Minimum Efficacious Doses in Combination Drug Trials.

Authors:  Julia N Soulakova; Allan R Sampson
Journal:  Stat Biopharm Res       Date:  2009       Impact factor: 1.452

9.  An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Authors:  Shahram Attarian; Jean-Michel Vallat; Laurent Magy; Benoît Funalot; Pierre-Marie Gonnaud; Arnaud Lacour; Yann Péréon; Odile Dubourg; Jean Pouget; Joëlle Micallef; Jérôme Franques; Marie-Noëlle Lefebvre; Karima Ghorab; Mahmoud Al-Moussawi; Vincent Tiffreau; Marguerite Preudhomme; Armelle Magot; Laurène Leclair-Visonneau; Tanya Stojkovic; Laura Bossi; Philippe Lehert; Walter Gilbert; Viviane Bertrand; Jonas Mandel; Aude Milet; Rodolphe Hajj; Lamia Boudiaf; Catherine Scart-Grès; Serguei Nabirotchkin; Mickael Guedj; Ilya Chumakov; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2014-12-18       Impact factor: 4.123

10.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Authors:  Petra Zieglmayer; Margarete Focke-Tejkl; René Schmutz; Patrick Lemell; René Zieglmayer; Milena Weber; Renata Kiss; Katharina Blatt; Peter Valent; Frank Stolz; Hans Huber; Angela Neubauer; Anette Knoll; Friedrich Horak; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2016-08-20       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.